Floatz logo

PEGASPARGASE

Myeloid Sarcoma

National Cancer Institute (NCI)protein_peptidePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

25 Active assets in the Myeloid Sarcoma cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
Kura Oncology, Inc.
Phase 3BB
Mitoxantrone
Ruijin Hospital
Phase 3BB
Daunorubicin
Kura Oncology, Inc.
Phase 3BB
ETOPOSIDE
St. Jude Children's Research Hospital
Phase 3BB
Venetoclax
Ruijin Hospital
Phase 2BB

View all 35 →

Same molecule, other indications

PEGASPARGASE is also rated in:

B-cell childhood acute lymphoblastic leukemiaDormant
A
Indicative ·
80 / 100
View asset →
Adult Acute Lymphocytic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
extranodal nasal NK/T cell lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →